Prostate Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Prostate Cancer, including details on symptoms, genetics, screening, treatment, information.

Detection rates of high-grade prostate cancer during subsequent screening visits. Results of the European Randomized Screening Study for Prostate Cancer.

van der Kwast TH, Ciatto S, Martikainen PM, Hoedemaeker R, Laurila M, Pihl CG, Hugosson J, Neetens I, Nelen V, Di Lollo S, Roobol MJ, Määtänen L, Santonja C, Moss S, Schröder FH

Department of Pathology and Urology, Erasmus Medical Center, Rotterdam, the Netherlands, and Centro per la Studio e la Prevenzione Oncologica, University of Florence, Italy. tvanderkwast@mtsinai.on.ca

Screening for prostate cancer using prostate-specific antigen (PSA) tests has led to a stage and grade shift as compared to the pre-PSA era. Effectiveness of screening for prostate cancer should be manifested by a reduction in detection rate of aggressive cancers during subsequent screening. In 6 centers of the European Randomized Screening study for Prostate Cancer, a total of 58,710 men were tested for prostate cancer. Screening centers differed with regard to age-range, screening interval and biopsy indications. During the 2nd visit, the proportion of Gleason score 6 cancers increased from 62.5 to 75%, mainly at the expense of Gleason score 7 cancers. High-grade (Gleason score 8-10) cancer detection rates varied per screening center during the 1st visit from 5.1 to 41.1, and during the 2nd visit from 6.4 to 29.3/10,000 men. The overall detection rate of high-grade cancers showed a reduction during the 2nd visit from 26 to 12/10,000 men, an effect mainly attributable to the screening center with the highest cancer detection rate (i.e. 507/10,000 men). Variations in detection rates among screening centers related among others to biopsy compliance and age range.

Published 6 March 2006 in Int J Cancer, 118(10): 2538-42.
Full-text of this article is available online (may require subscription).

© 2004-2008 Prostate Cancer Research Today. All Rights Reserved.